Insider Stock Sales
Pharvaris Insiders Sell Major Shares as Stock Trades Near 52-Week High
Anonymous
Key Points
1
Robert Glassman’s 8,000-share sale reduced his Pharvaris holdings by 43.24%, leaving him with shares valued at approximately $394,275.
2
Anne Lesage’s late-June sales totaled 76,172 shares across four transactions, with proceeds of roughly $2.70 million; the sales occurred on June 29 and June 30 at prices ranging from $35.05 to $35.49.
3
Pharvaris reported a quarterly loss of $0.81 per share, missing analysts’ consensus estimate of a $0.75 loss per share by $0.06.
4
Analyst sentiment included target-price increases from Guggenheim, which raised its target to $44, Wells Fargo, which raised its target to $65, and Leerink Partners, which also lifted its target to $65; Wedbush increased its target to $50.
5
The stock’s reported beta was -2.33, while its 50-day and 200-day moving averages were approximately $35.09 and $31.41, respectively, indicating that the share price was trading above both recent average levels.
Pharvaris insiders unloaded 38,000 shares this week, signaling mixed confidence in the biotech company. Director Robert Glassman sold 8,000 shares for roughly $300,400, while insider Anne Lesage dumped 30,000 shares at an average of $38.30 per share for about $1.15 million according to watchlistnews. Both sales were executed under Rule 10b5-1 trading plans—prearranged agreements designed to reduce concerns about trading on inside information.
Insider Selling Reduces Leadership Stakes
Glassman's sale cut his holdings by 43.24 percent, leaving him with 10,500 shares worth roughly $394,275 according to watchlistnews. Lesage's move was much larger. She offloaded 30,000 shares this week alone, keeping 56,450 shares on the books. In late June, Lesage had already sold 76,172 shares across four transactions for approximately $2.70 million at prices ranging from $35.05 to $35.49.
Stock Trading Near 52-Week High Despite Losses
Pharvaris shares are trading near their 52-week high, with a 50-day moving average of $35.09 and 200-day average of $31.41. Yet the company continues to bleed money. Last quarter, Pharvaris reported a loss of $0.81 per share, beating analyst expectations by only $0.06 and missing the consensus estimate of a $0.75 loss.
Multiple analysts have raised price targets recently. Guggenheim lifted its target to $44, while Wells Fargo and Leerink Partners both increased theirs to $65. Wedbush pushed its target to $50. These bullish calls suggest the market believes the company's losses are temporary.
Rule 10b5-1 Plans Shield Insiders From Accusations
Both executives used Rule 10b5-1 trading plans, a mechanism that lets company insiders sell shares on a fixed schedule without triggering accusations of trading on secret information according to watchlistnews. The plans are designed to reduce legal risk. Instead of selling when they have access to material nonpublic data, insiders set up automatic sales weeks or months in advance.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
17
Articles
12
Reach
29
A
AnonymousAuthor
